While the difference in survival following ATRi QDx3 plus RT plus anti–PD-L1 versus RT plus PD-L1 did not reach statistical significance, the addition of ATRi QDx3 increased the number of complete responses (complete tumor clearance) from 1 of 13 mice treated with RT plus anti–PD-L1 to 4 of 14 mice treated with ATRi QDx3 plus RT plus anti–PD-L1 (Figure 8D and Supplemental Figure 8). This evidence concerns the gene CD274 and neoplasm.